Scholarlink

<p>For precise personalized treatment of triple-negative breast cancer (TNBC) and inhibition of its metastasis, we innovatively designed and synthesized a gadolinium (III)–copper(I) complex (<b>GdCu</b>) with remarkable performance in T<sub>1</sub>-weighted magnetic resonance imaging (MRI) and cytotoxicity to TNBC cells. In addition, we constructed a <b>GdCu</b>@apoferritin (AFt) nanoparticles (NPs) delivery system. <b>GdCu</b> and <b>GdCu</b>@AFt NPs significantly inhibited the migration and invasion of MDA-MB-231 cells in vitro. <b>GdCu</b> can significantly inhibit the growth and metastasis of TNBC in vivo. <b>GdCu</b>@AFt NPs not only improved the targeting ability of <b>GdCu</b>, showed an enhanced performance of MRI and tumor-growth inhibition, but also decreased the systemic toxicity of <b>GdCu</b> in vivo. We demonstrated that <b>GdCu</b> and <b>GdCu</b>@AFt NPs prevented the growth and metastasis of TNBC by inducing mitochondria-mediated apoptosis and inhibiting cancer cell stemness. The remarkable MRI, anticancer and anti-metastasis capabilities of <b>GdCu</b> and <b>GdCu</b>@AFt NPs make them promising agents for the targeted theranostics of TNBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design of a theranostic Gd (III)–Cu (I) complex to inhibit growth and metastasis of triple-negative breast cancer

  • 期刊论文

  • 发表日期：

    2025年1月9日

查看全文
  • Xue-Yu Man,
  • Ming-Hui Zhu,
  • Shan-He Li,
  • Wen-Juan Li,
  • Gang Xu,
  • Zhen-Lei Zhang,
  • Xiao-Yang Wu,
  • Hong Liang,
  • Feng Yang

摘要

For precise personalized treatment of triple-negative breast cancer (TNBC) and inhibition of its metastasis, we innovatively designed and synthesized a gadolinium (III)–copper(I) complex (GdCu) with remarkable performance in T1-weighted magnetic resonance imaging (MRI) and cytotoxicity to TNBC cells. In addition, we constructed a GdCu@apoferritin (AFt) nanoparticles (NPs) delivery system. GdCu and GdCu@AFt NPs significantly inhibited the migration and invasion of MDA-MB-231 cells in vitro. GdCu can significantly inhibit the growth and metastasis of TNBC in vivo. GdCu@AFt NPs not only improved the targeting ability of GdCu, showed an enhanced performance of MRI and tumor-growth inhibition, but also decreased the systemic toxicity of GdCu in vivo. We demonstrated that GdCu and GdCu@AFt NPs prevented the growth and metastasis of TNBC by inducing mitochondria-mediated apoptosis and inhibiting cancer cell stemness. The remarkable MRI, anticancer and anti-metastasis capabilities of GdCu and GdCu@AFt NPs make them promising agents for the targeted theranostics of TNBC.